The Memory Enhancement Center of America, Inc. Report issue

Academic/Hospital Phase 2
Founded: Eatontown NJ United States (2011)

Organization Overview

First Clinical Trial
2011
NCT01761045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Memory Enhancement Center of America | Memory Enhancement Center of America, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

chf5074 (4 trials)

Drugs in Other Trials (2)

monosodium glutamate (1 trial)

nucleic acids (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Nerve Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3